« Return to News | CROs/Service Providers

Molecular Imaging partners with Dana-Faber Cancer Institute

Thursday, December 15, 2011 08:15 AM

Molecular Imaging has entered into a licensing agreement with Dana-Farber Cancer Institute to access a substantial number of luciferase-enabled cancer cell lines developed at Dana-Farber. Access to these lines expands Molecular Imaging’s ability to apply bioluminescent imaging technology to a broad array of cancer disease models, including expanded capability in various leukemias, multiple myeloma, triple-negative breast cancer, glioma and melanoma.  

“This licensing relationship gives Molecular Imaging access to over 100 additional luc-enabled cell lines, providing the ability to use imaging in a much broader array of cancer disease models, with greater confidence.  Access to the knowledge and skills of Drs Kung and Armstrong only makes the opportunity to advance the science of imaging more compelling.  We look forward to collaborating with Andrew and Scott in making these cell lines available as part of our services to pharmaceutical and biotechnology companies to enhance R&D decision-making,” said W. R. Leopold, PhD, VP, research and development, at Molecular.

Molecular Imaging expects to nearly triple its validated luc-reporter cell line library by end of first quarter 2012. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.